卡托普利（用于治疗高血压）的上市后监测：初步报告。
Post marketing surveillance of captopril (for hypertension): a preliminary report.
作者信息
Chalmers D, Dombey S L, Lawson D H
机构信息
Medical & Scientific Affairs, E.R. Squibb & Sons Ltd., Hounslow, Middlesex.
出版信息
Br J Clin Pharmacol. 1987 Sep;24(3):343-9. doi: 10.1111/j.1365-2125.1987.tb03179.x.
Abstract
1 The methodology and interim results of a post marketing surveillance of captopril, the first orally active angiotensin converting enzyme inhibitor are presented. 2 Utilising viewdata technology, details of hypertensive patients were entered directly into a mainframe computer. This allowed day to day monitoring of events; a facility not available with paper-based methods. 3 The design of the study allowed analysis of results including some details of efficacy, concomitant therapy, any disease symptoms and reasons for withdrawal. These factors could be categorised according to sex and age. 4 This preliminary report is based on the first 13,295 patients entered from July 1983 with follow-up until January 1985. The results of the study confirm the safety of captopril in the patients studied.
摘要
1 本文介绍了首个口服活性血管紧张素转换酶抑制剂卡托普利上市后监测的方法和中期结果。2 利用可视数据技术，高血压患者的详细信息直接输入大型计算机。这使得能够对事件进行日常监测，这是基于纸质方法所没有的便利。3 该研究的设计允许对结果进行分析，包括疗效的一些细节、联合治疗、任何疾病症状以及停药原因。这些因素可按性别和年龄进行分类。4 这份初步报告基于1983年7月至1985年1月录入的首批13295例患者，研究结果证实了卡托普利在所研究患者中的安全性。
相似文献
1
Post marketing surveillance of captopril (for hypertension): a preliminary report.卡托普利（用于治疗高血压）的上市后监测：初步报告。
Br J Clin Pharmacol. 1987 Sep;24(3):343-9. doi: 10.1111/j.1365-2125.1987.tb03179.x.
2
Postmarketing surveillance of captopril for hypertension.卡托普利治疗高血压的上市后监测。
Br J Clin Pharmacol. 1992 Sep;34(3):215-23. doi: 10.1111/j.1365-2125.1992.tb04127.x.
3
4
5
Captopril in hypertension; seven years later.
J Cardiovasc Pharmacol. 1985;7 Suppl 1:S96-101.
6
7
Captopril: 4 years of post marketing surveillance of all patients in New Zealand.卡托普利：对新西兰所有患者进行的4年上市后监测。
Br J Clin Pharmacol. 1987 May;23(5):529-36. doi: 10.1111/j.1365-2125.1987.tb03088.x.
8
[Long term treatment of resistant hypertension with captopril (author's transl)].
Nouv Presse Med. 1981 Apr 30;10(19):1565-9.
9
[Blood pressure and metabolic response to converting enzyme inhibitor in hypertensive patients: comparison between delapril and captopril].[高血压患者对转换酶抑制剂的血压和代谢反应：地拉普利与卡托普利的比较]
J Formos Med Assoc. 1992 Dec;91 Suppl 4:S288-92.
10
Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group.男性的生活质量与抗高血压治疗。卡托普利与依那普利的比较。生活质量高血压研究组。
N Engl J Med. 1993 Apr 1;328(13):907-13. doi: 10.1056/NEJM199304013281302.
引用本文的文献
1
Zofenopril and incidence of cough: a review of published and unpublished data.佐芬普利和咳嗽的发生：已发表和未发表数据的综述。
Ther Clin Risk Manag. 2011;7:459-71. doi: 10.2147/TCRM.S25976. Epub 2011 Nov 29.
2
Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy.氯沙坦与卡托普利对有症状心力衰竭老年患者生活质量影响的随机对照研究：氯沙坦心力衰竭ELITE生活质量子研究
Qual Life Res. 2000;9(4):377-84. doi: 10.1023/a:1008948930206.
3
Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients.培哚普利上市后监测：对47351例高血压患者进行的12个月研究。
Br J Clin Pharmacol. 1998 Jul;46(1):63-70. doi: 10.1046/j.1365-2125.1998.00031.x.
4
The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study.ELITE研究。其对心力衰竭药物治疗有何启示？老年患者中氯沙坦的评估研究。
Drugs Aging. 1998 Jun;12(6):423-8. doi: 10.2165/00002512-199812060-00001.
5
ACE inhibitor-induced angioedema. Incidence, prevention and management.血管紧张素转换酶抑制剂引起的血管性水肿。发病率、预防及管理
Drug Saf. 1998 Mar;18(3):171-88. doi: 10.2165/00002018-199818030-00003.
6
Optimal dosage of ACE inhibitors in older patients.老年患者中血管紧张素转换酶抑制剂的最佳剂量
Drugs Aging. 1996 Oct;9(4):262-73. doi: 10.2165/00002512-199609040-00004.
7
European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort.
Eur J Clin Pharmacol. 1995;49(1-2):73-9. doi: 10.1007/BF00192362.
8
Choosing the right ACE inhibitor. A guide to selection.选择合适的血管紧张素转换酶抑制剂。选择指南。
Drugs. 1995 Apr;49(4):516-35. doi: 10.2165/00003495-199549040-00003.
9
Post-marketing surveillance or drug acceptability study?上市后监测还是药物可接受性研究？
Br J Clin Pharmacol. 1987 Sep;24(3):281-2. doi: 10.1111/j.1365-2125.1987.tb03170.x.
10
Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.卡托普利。其药效学和药代动力学特性的最新进展，以及在高血压和充血性心力衰竭中的治疗应用。
Drugs. 1988 Nov;36(5):540-600. doi: 10.2165/00003495-198836050-00003.
本文引用的文献
1
Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study.西咪替丁与胃癌：上市后监测研究的初步报告
Br Med J (Clin Res Ed). 1982 Nov 6;285(6351):1311-3. doi: 10.1136/bmj.285.6351.1311.
2
Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton.全科医疗中药物不良反应的上市后监测。II：南安普顿大学的处方事件监测。
Br Med J (Clin Res Ed). 1981 Apr 11;282(6271):1216-7. doi: 10.1136/bmj.282.6271.1216.
3
Postmarketing surveillance: practical experience with ketotifen.上市后监测：酮替芬的实际应用经验
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):911-4. doi: 10.1136/bmj.288.6421.911.
4
Postmarketing surveillance of the safety of cimetidine: 12 month mortality report.西咪替丁安全性的上市后监测：12个月死亡率报告。
Br Med J (Clin Res Ed). 1983 May 28;286(6379):1713-6. doi: 10.1136/bmj.286.6379.1713.
5
Drug rash with ampicillin and other penicillins.
Lancet. 1969 Nov 8;2(7628):969-72. doi: 10.1016/s0140-6736(69)90535-2.
6
Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report.西咪替丁安全性的上市后监测：十二个月发病率报告。
Q J Med. 1985 Mar;54(215):253-68.
7
Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up.西咪替丁安全性的上市后监测：随访第二、三、四年期间的死亡率
Br Med J (Clin Res Ed). 1985 Oct 19;291(6502):1084-8. doi: 10.1136/bmj.291.6502.1084.
8
The effects of antihypertensive therapy on the quality of life.抗高血压治疗对生活质量的影响。
N Engl J Med. 1986 Jun 26;314(26):1657-64. doi: 10.1056/NEJM198606263142602.
9
Angiotensin-converting enzyme inhibitors: past, present, and bright future.血管紧张素转换酶抑制剂：过去、现在与光明未来。
Lancet. 1985 Jan 5;1(8419):30-4. doi: 10.1016/s0140-6736(85)90975-4.
10
Post-marketing surveillance of adverse reactions to new medicines.新药不良反应的上市后监测
Br Med J. 1977 Oct 15;2(6093):1001-3. doi: 10.1136/bmj.2.6093.1001.
Zotero 插件